• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term outcomes of relapsed/refractory double-hit lymphoma (r/r DHL) treated with CD19/22 CAR T-cell cocktail therapy.

作者信息

Wei Jia, Mao Zekai, Wang Na, Huang Lifang, Cao Yang, Sun Weimin, Long Xiaolu, Tan Jiaqi, Li Chunrui, Xiao Yi, Gu Chaojiang, Zhang Shangkun, Zhang Yicheng, Zhang Tongcun, Zhou Jianfeng, Huang Liang

机构信息

Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China.

出版信息

Clin Transl Med. 2020 Sep;10(5):e176. doi: 10.1002/ctm2.176.

DOI:10.1002/ctm2.176
PMID:32997409
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7507504/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1473/7507504/cf9c91c1ce0f/CTM2-10-e176-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1473/7507504/cf9c91c1ce0f/CTM2-10-e176-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1473/7507504/cf9c91c1ce0f/CTM2-10-e176-g001.jpg

相似文献

1
Long-term outcomes of relapsed/refractory double-hit lymphoma (r/r DHL) treated with CD19/22 CAR T-cell cocktail therapy.接受CD19/22嵌合抗原受体T细胞联合疗法治疗的复发/难治性双打击淋巴瘤（r/r DHL）的长期预后
Clin Transl Med. 2020 Sep;10(5):e176. doi: 10.1002/ctm2.176.
2
T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells.携带抗 CD19 和/或抗 CD38 嵌合抗原受体的 T 细胞能有效消除原发性双打击淋巴瘤细胞。
J Hematol Oncol. 2017 Jun 8;10(1):116. doi: 10.1186/s13045-017-0488-x.
3
Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.在 MYC、BCL2 和/或 BCL6 重排的复发或难治性弥漫性大 B 细胞淋巴瘤中，自体干细胞移植和嵌合抗原受体 T 细胞治疗的利用模式和结局。
Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):825-834. doi: 10.1016/j.clml.2022.06.011. Epub 2022 Jun 29.
4
Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience.真实世界中 axicabtagene ciloleucel 和 tisagenlecleucel 治疗复发/难治侵袭性 B 细胞淋巴瘤的经验：单中心经验。
Clin Lymphoma Myeloma Leuk. 2021 Dec;21(12):861-872. doi: 10.1016/j.clml.2021.07.002. Epub 2021 Jul 19.
5
Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma.人源化与鼠源化 CD19 和 CD22 CAR-T 细胞鸡尾酒疗法治疗难治/复发 B 细胞淋巴瘤的安全性和有效性。
Cells. 2022 Dec 16;11(24):4085. doi: 10.3390/cells11244085.
6
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma.ASCTCT 弥漫性大 B 细胞淋巴瘤移植和细胞治疗临床实践建议
Transplant Cell Ther. 2023 Sep;29(9):548-555. doi: 10.1016/j.jtct.2023.06.012. Epub 2023 Jul 5.
7
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.采用 RV-SFG.CD19.CD28.4-1BBzeta 逆转录病毒载体转导的 T 淋巴细胞治疗复发或难治性 CD19+淋巴组织疾病患者的单中心 I/II 期临床试验方案。
BMJ Open. 2019 May 19;9(5):e026644. doi: 10.1136/bmjopen-2018-026644.
8
A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.双特异性CD19/22嵌合抗原受体T细胞疗法治疗复发或难治性B细胞非霍奇金淋巴瘤患者的前瞻性研究。
Front Oncol. 2021 May 25;11:664421. doi: 10.3389/fonc.2021.664421. eCollection 2021.
9
Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk.强化减瘤化疗可提高抗CD19嵌合抗原受体T细胞（Anti-CD19-CAR-T）对高肿瘤负荷的难治性/复发性弥漫性大B细胞淋巴瘤（DLBCL）的短期和长期疗效。
Front Oncol. 2021 Jul 30;11:706087. doi: 10.3389/fonc.2021.706087. eCollection 2021.
10
Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.双打击或三打击病理对复发或难治性大 B 细胞淋巴瘤患者放疗反应率和持久性的影响。
Pract Radiat Oncol. 2020 Jan-Feb;10(1):44-52. doi: 10.1016/j.prro.2019.09.013. Epub 2019 Oct 1.

引用本文的文献

1
Targets for CAR Therapy in Multiple Myeloma.多发性骨髓瘤中CAR疗法的靶点
Int J Mol Sci. 2025 Jun 24;26(13):6051. doi: 10.3390/ijms26136051.
2
Outcome of high-grade B-cell lymphoma compared with other large B-cell lymphoma after CAR-T rescue: a DESCAR-T LYSA study.嵌合抗原受体T细胞（CAR-T）挽救治疗后高级别B细胞淋巴瘤与其他大B细胞淋巴瘤的结局：一项DESCAR-T LYSA研究
Blood Adv. 2025 May 27;9(10):2500-2510. doi: 10.1182/bloodadvances.2024014732.
3
CAR-T cell combination therapies in hematologic malignancies.血液系统恶性肿瘤中的嵌合抗原受体T细胞联合疗法。

本文引用的文献

1
Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies.CAR19/22 T 细胞鸡尾酒疗法治疗难治/复发性 B 细胞恶性肿瘤患者的疗效和安全性。
Blood. 2020 Jan 2;135(1):17-27. doi: 10.1182/blood.2019000017.
2
Rapid and sustained response to Chimeric Antigen Receptor T cell therapy in double hit diffuse large B cell lymphoma.双打击弥漫性大B细胞淋巴瘤对嵌合抗原受体T细胞疗法的快速且持续反应
Am J Hematol. 2020 Mar;95(3):333-334. doi: 10.1002/ajh.25621. Epub 2019 Sep 9.
3
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Exp Hematol Oncol. 2024 Jul 18;13(1):69. doi: 10.1186/s40164-024-00536-0.
4
Recent advances in CAR-T cell therapy for acute myeloid leukaemia.嵌合抗原受体 T 细胞疗法治疗急性髓系白血病的最新进展。
J Cell Mol Med. 2024 May;28(9):e18369. doi: 10.1111/jcmm.18369.
5
Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.优化血液系统恶性肿瘤嵌合抗原受体 T 细胞治疗的策略：中国经验。
Haematologica. 2023 Aug 1;108(8):2011-2028. doi: 10.3324/haematol.2022.282316.
6
Editorial: The mechanism and novel strategies of overcoming resistance of hematological malignancies to CAR-T cell killing.社论：血液系统恶性肿瘤对CAR-T细胞杀伤产生抗性的机制及克服抗性的新策略
Front Immunol. 2022 Dec 9;13:1093339. doi: 10.3389/fimmu.2022.1093339. eCollection 2022.
7
Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.联合策略优化嵌合抗原受体 T 细胞疗法在血液恶性肿瘤中的疗效。
Front Immunol. 2022 Aug 23;13:954235. doi: 10.3389/fimmu.2022.954235. eCollection 2022.
8
Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.嵌合抗原受体修饰的 T 细胞免疫疗法治疗复发/难治性成人伯基特淋巴瘤。
Front Immunol. 2022 May 20;13:879983. doi: 10.3389/fimmu.2022.879983. eCollection 2022.
9
T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma.T 细胞缺陷：弥漫性大 B 细胞淋巴瘤中 CD19/CD22 鸡尾酒 CAR T 细胞免疫治疗原发性耐药的新见解。
Front Immunol. 2022 Apr 27;13:873789. doi: 10.3389/fimmu.2022.873789. eCollection 2022.
10
Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT.单独或联合 ASCT 使用 CAR T 细胞鸡尾酒治疗伴有 TP53 改变的侵袭性 B 细胞淋巴瘤的结果。
Signal Transduct Target Ther. 2022 Apr 11;7(1):101. doi: 10.1038/s41392-022-00924-0.
阿基仑赛注射液治疗难治性大 B 细胞淋巴瘤的长期安全性和疗效（ZUMA-1）：一项单臂、多中心、1-2 期临床试验。
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
4
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
5
High-grade B-cell lymphoma with and and/or rearrangements with diffuse large B-cell lymphoma morphology.伴有 和/或 重排的高级别 B 细胞淋巴瘤，伴弥漫性大 B 细胞淋巴瘤形态学特征。
Blood. 2018 May 3;131(18):2060-2064. doi: 10.1182/blood-2017-12-820605. Epub 2018 Feb 23.
6
Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma.DA-EPOCH-R诱导化疗加自体移植巩固治疗双打击淋巴瘤的疗效
Leuk Lymphoma. 2018 Aug;59(8):1884-1889. doi: 10.1080/10428194.2017.1406085. Epub 2017 Dec 3.
7
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.难治性弥漫性大B细胞淋巴瘤的预后：国际SCHOLAR-1研究结果
Blood. 2017 Oct 19;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620. Epub 2017 Aug 3.
8
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.复发或难治性双表达和双打击淋巴瘤在自体干细胞移植后的无进展生存期较差。
J Clin Oncol. 2017 Jan;35(1):24-31. doi: 10.1200/JCO.2016.68.2740. Epub 2016 Oct 24.
9
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗弥漫性大 B 细胞淋巴瘤时 MYC 和 BCL2 的共表达。
J Clin Oncol. 2012 Oct 1;30(28):3452-9. doi: 10.1200/JCO.2011.41.0985. Epub 2012 Jul 30.
10
MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.MYC 阳性弥漫性大 B 细胞淋巴瘤经经典 R-ICE 或 R-DHAP 挽救治疗后序贯 BEAM 方案并自体造血干细胞移植治疗无效。
Blood. 2012 May 17;119(20):4619-24. doi: 10.1182/blood-2012-01-406033. Epub 2012 Mar 9.